FDA Updates Guidance for Data Monitoring Committees

Since its first Guidance Document for Data Monitoring Committees (DMCs) in 2006, the role of DMCs in clinical trial and clinical development programs has expanded exponentially. Sponsors frequently debate the purpose, scope, and limitations of DMCs which in turn increases the time and cost to set-up these and creates confusing practices for their activities. Hence, … Read more